Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.
Göteborg, Sweden. In Mol Neurodegener, Dec 2015
BACKGROUND: The discovery that heterozygous missense mutations in the gene encoding triggering receptor expressed on myeloid cells 2 (TREM2) are risk factors for Alzheimer's disease (AD), with only the apolipoprotein E (APOE) ε4 gene allele conferring a higher risk, has led to increased interest in immune biology in the brain.
A Comprehensive Review of Immunoreceptor Regulation of Osteoclasts.
Oklahoma City, United States. In Clin Rev Allergy Immunol, Dec 2015
DAP12 pairs with a number of different immunoreceptors including triggering receptor expressed on myeloid cells 2 (TREM2), myeloid DAP12-associated lectin (MDL-1), and sialic acid-binding immunoglobulin-type lectin 15 (Siglec-15); while FcRγ pairs with a different set of receptors including osteoclast-specific activating receptor (OSCAR), paired immunoglobulin receptor A (PIR-A), and Fc receptors.
Variant of TREM2 associated with the risk of Alzheimer's disease.
Reykjavík, Iceland. In N Engl J Med, 2013
RESULTS: A rare missense mutation (rs75932628-T) in the gene encoding the triggering receptor expressed on myeloid cells 2 (TREM2), which was predicted to result in an R47H substitution, was found to confer a significant risk of Alzheimer's disease in Iceland (odds ratio, 2.92; 95% confidence interval [CI], 2.09 to 4.09; P=3.42×10(-10)).
TREM2 variants in Alzheimer's disease.
London, United Kingdom. In N Engl J Med, 2013
BACKGROUND: Homozygous loss-of-function mutations in TREM2, encoding the triggering receptor expressed on myeloid cells 2 protein, have previously been associated with an autosomal recessive form of early-onset dementia.